menu
    • menu
    [{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Allopurinol","moa":"Xanthine dehydrogenase","graph1":"Rheumatology","graph2":"Approved FDF","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Indoco Remedies Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Indoco Remedies Limited \/ Undisclosed"},{"orgOrder":0,"company":"dr. M.J.N.L. Benders","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Allopurinol","moa":"Xanthine dehydrogenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"dr. M.J.N.L. Benders","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"dr. M.J.N.L. Benders \/ ZonMw","highestDevelopmentStatusID":"10","companyTruncated":"dr. M.J.N.L. Benders \/ ZonMw"},{"orgOrder":0,"company":"Crystalys Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series A Financing","leadProduct":"Dotinurad","moa":"||Solute carrier family 22 member 12","graph1":"Rheumatology","graph2":"Phase III","graph3":"Crystalys Therapeutics","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rheumatology","amount2New":0.20999999999999999,"dosageForm":"Tablet","sponsorNew":"Crystalys Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Crystalys Therapeutics \/ Novo Holdings"}]

    Find Clinical Drug Pipeline Developments & Deals for Allorin

    Menu

    Allorin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Crystalys Therapeutics

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Crystalys Therapeutics

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dotinurad,Allopurinol

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Novo Holdings

                            Deal Size : $205.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Novo-Backed Crystalys Debuts With $205M to Tackle Gout

                            Details : The financing round will support the advancement of Phase 3 evaluating, FYU-981 (dotinurad), a next-generation, once daily oral, URAT1 inhibitor for the treatment of gout.

                            Product Name : FYU-981

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 30, 2025

                            Lead Product(s) : Dotinurad,Allopurinol

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Novo Holdings

                            Deal Size : $205.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Indoco Remedies Limited

                            India arrow
                            FNCE
                            Not Confirmed

                            Indoco Remedies Limited

                            India arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Rheumatology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Indoco Remedies Gains USFDA Final Approval for Allopurinol Tablets USP 200 mg

                            Details : Zyloprim-Generic (allopurinol) is a xanthine oxidase inhibitor. It is indicated for the treatment of primary or secondary gout, leukemia, lymphoma and solid tumor malignancies.

                            Product Name : Zyloprim-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 23, 2025

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            dr. M.J.N.L. Benders

                            Country arrow
                            FNCE
                            Not Confirmed

                            dr. M.J.N.L. Benders

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : ZonMw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring ...

                            Details : Allopurinol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Defects, Congenital.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 03, 2020

                            Lead Product(s) : Allopurinol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : ZonMw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth